News & Updates
Filter by Specialty:
Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
Inflammatory bowel disease (IBD) patients receiving treatment with antitumour necrosis factor alpha (anti-TNFα) for more than 2 years represent a distinct group who obtain prolonged clinical benefit and tolerate maintenance treatment, according to a study.
Sustained benefit with anti-TNFα less likely to lead to subsequent loss of response in IBD
01 Nov 2021
Post-ICH antiplatelet therapy not linked to recurrent ICH
Initiating antiplatelet therapy following an intracerebral haemorrhage (ICH) that occurred during antithrombotic use does not lead to recurrent symptomatic ICH, according to extended results of the RESTART* trial.
Post-ICH antiplatelet therapy not linked to recurrent ICH
28 Oct 2021
ULTIMATE: Biologic DMARD affords inflammation control in psoriatic arthritis
Interleukin-17 inhibition with the biologic disease-modifying antirheumatic drug (DMARD) secukinumab appears to produce a substantial reduction in synovitis in psoriatic arthritis, in addition to improvements in the signs and symptoms of the disease, according to the results of the phase III ULTIMATE.